Praxis Q2: $1.4B Cash, Two PDUFAs on Track, No FDA Red Flags
PRAX has more than doubled off its 52-week low of $37.19.
Summary
Praxis Precision Medicines reported Q2 2026 earnings with $1.4B in cash, confirmed both ulixacaltamide and relutrigine are on track for PDUFA dates with no FDA red flags, and advanced commercial preparations for two potential first-in-class CNS launches.
Key Events · Earnings and Guidance · PRAX
-
Q2 2026 Financial Results
Net loss of $83.7M ($2.87/share) on operating expenses of $96.9M. Cash and investments totaled $1.4B as of June 30, 2026, expected to fund operations into 2028.
-
Regulatory Milestones Achieved
Mid-cycle meetings completed for both ulixacaltamide and relutrigine with no major safety/efficacy concerns; FDA confirmed no advisory committee meetings planned. BIMO inspections completed with no Form 483 observations.
-
PDUFA Dates Confirmed
Relutrigine PDUFA date December 27, 2026; ulixacaltamide PDUFA date January 29, 2027. Both NDAs under priority review.
-
Commercial Launch Preparations
Commercial leadership in place, field force hiring underway, distribution network established, and inventory build in progress for both ulixacaltamide and relutrigine.
Analysis · PRAX · Life Sciences
Praxis reported Q2 2026 results with $1.4 billion in cash, funding operations into 2028. The update confirms both ulixacaltamide (essential tremor) and relutrigine (DEEs) remain on track for PDUFA dates in January and December 2027, respectively, with mid-cycle reviews completed and no major safety or efficacy concerns raised by the FDA. BIMO inspections for both programs were completed with no Form 483 observations, and no advisory committee meetings are planned. Commercial launch preparations are accelerating. The company also announced the restart of the POWER2 study for vormatrigine and initiation of POWER3 in Q4 2026, and a third Breakthrough Therapy Designation for elsunersen. With two potential first-in-class approvals within six months and a cash runway into 2028, the quarter reinforces Praxis's transition toward becoming a multi-product commercial CNS company.
At the time of this filing, PRAX was trading at $337.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $37.19 to $366.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.